french rotavirus 2014x
Post on 01-Feb-2016
47 Views
Preview:
DESCRIPTION
TRANSCRIPT
French Rotavirus 2014.pptx 3/25/2013 11:36 AM
Govera
Characteristics ofNaturally-Occurring Intussusception
• Etiology not well defined• Uncommon: Incidence ~1/2000
infant-years• Peak incidence is between 5 and 9
months of age• Male to female case ratio = 1.5-4:1• Treated with enema or surgery• Morbidity and mortality low if
treated early; however, delay in diagnosis may be fatal
For Training Purposes 21
New Rotavirus Vaccines
Glass RI, et al. Transactions of the American and Climatological Association,Vol. 123, 2012, page 36-53.
Effet Indirect SurLa Maladie Rota
Chez Adultes, USA
Années % Selles Positif
2006-07 4.35%
2008-10 2.24%
48%
Anderson et al. CID, 2013
Rotavirus Hospitalizations among Children <5 yrsEl Salvador, Jan 2006 – December 2009
L’Efficacité des Vaccins RotaContre La Maladie Grave Par
Dose Aux Etats-Unis
Doses RV5 RV1
3 87-92% NA
2 78-90% 70-91%
1 65-74% 53-57%
Zickafoose JS, Arch Peds Adolesc Med, Vol 166(4):350, 2012
Hospitalizations Pour Invagination Intestinale USAAvant et Aprés Introduction du Vaccin Rotavirus Pentavalent
Invagination Intestinale
Selon le CDC Américainle RV5 induit 1 dans 100,000 vaccinations
le RV1 induit 1 dans 20,000wais les limitee confiances sont larges
Vaccination Contre GastroentériteRotavirus Grave en Pays Tropicaux
Vaccin Pays Efficacité
RV1 Brasil 77%
Malawi 49%
Afrique Sud 77%
Bolivia 69%
RV5 Nicaragua 77%
Kenya 83%
Ghana 65%
Viet Nam 73%
Bangladesh 46%
Appaiahgari MB, et al. Vaccine 32:651-6, 2014
Souche Néonatale Indienne ORV-116E est moins immunogène quand les anticorps maternels sont élévés
Prédiction des Morts Evités, 2011-2030Par Vaccination Rotavirus Dans les Pays
Admissibles Pour Soutien par GAVI
Region Morts
Amérique 39,140
Europe 24,270
Afrique 1,352870
Moyen Orient 549,830
Asie Sudest 482,300
Pacifique 10,100
Total 2,458,510 Athe
rly, V
acci
ne, 2
012
Effectiveness of Rotavirus Vaccines
RV5 RV1
Stratum Cases/Controls
VE (95% CI) Cases/Controls
VE (95% CI)
Dose 1 233/537 70% (50%-82%) 46/83 57% (-45% to 87%)
Dose 2 239/638 78% (65%-86%) 56/140 70% (39% to 86%)
Dose 3 307/1445 84% (78%-88%) NA NA
Payne DC, et al. CID 2013:57(1):13-20
top related